ExplORer Surgical
Series A in 2019
ExplORer Surgical Corp. is a Chicago-based company that specializes in developing an interactive surgical playbook aimed at enhancing teamwork and efficiency in operating rooms. Founded in 2013, the company offers a software solution that allows healthcare providers to optimize surgical workflows, customize processes based on patient needs and surgeon preferences, and track case progression in real time. This tool facilitates improved communication among surgical teams, enabling them to coordinate activities and manage tools and supplies effectively, ultimately reducing disruptions and waste. Additionally, ExplORer Surgical provides administrators with valuable performance and scheduling data to enhance the quality of care. The company's innovative approach not only supports surgical teams but also assists medical device companies in the efficient rollout of new devices and improves medical education.
Respicardia
Series D in 2013
Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.
Sonitus Medical
Series D in 2012
Sonitus Medical Inc. is a privately held medical device company based in San Mateo, California, focused on delivering innovative hearing solutions for patients with hearing challenges. The company specializes in bone conduction hearing devices and markets the SoundBite Hearing System, which is recognized as the world's first non-invasive and removable hearing solution that transmits sound through the teeth. This nearly invisible in-the-mouth hearing system is designed to address single-sided deafness and conductive hearing loss, providing a simple and non-surgical alternative for patients. The device is currently FDA cleared as a prosthetic for these specific conditions. Sonitus Medical aims to expand its technology to include treatments for mixed hearing loss and tinnitus, as well as applications in consumer and covert communications. Founded in 2006, Sonitus Medical is emerging as a leader in the field of hearing solutions.
Uptake Medical
Series C in 2012
Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.
iScience Interventional
Venture Round in 2012
iScience Interventional specializes in developing innovative medical technologies for ophthalmic interventions. They focus on creating advanced microcatheters and imaging systems, enabling eye specialists to precisely administer therapies to specific locations within the eye. Additionally, they offer medical devices for canaloplasty procedures.
Respicardia
Series C in 2010
Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.
Uptake Medical
Series B in 2010
Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.
Baxano, Inc. is a medical device company specializing in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Founded in 2005 and based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in the foramen, lateral recess, and central canal, catering to patients with varying degrees of spinal stenosis. Baxano's product lineup includes the Neuro Check device, which enables surgeons to verify safe positioning against the bone while ensuring the nerve is adequately protected. Additionally, it features the MicroBlade Shaver, an instrument for removing impinging bone and ligament, along with essential accessories such as guidewires, probes, and distal handles.
Anulex Technologies
Series E in 2010
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).
Hemosphere
Series A in 2010
Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.
ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, that specializes in developing innovative therapy solutions for patients suffering from obesity and obesity-related metabolic disorders. Founded in 2002, ValenTx focuses on minimally-invasive treatment methods, including an endoluminal bypass therapy that replicates the anatomical changes of the traditional Roux-en-Y gastric bypass procedure. This technology features an adjustable, removable, and replaceable device designed to address conditions such as type-2 diabetes and hypertension, aiming to improve patient outcomes in the management of these chronic health issues.
CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in the research and development of innovative therapies and treatment solutions for cerebral ischemia. The company focuses on creating devices that control blood flow to the brain, specifically through its neuroflo and flocontrol products. These devices are designed to divert blood flow in patients, thereby helping to reduce the risk of strokes and heart attacks, particularly in individuals experiencing vasospasm and heart blockage. CoAxia aims to improve patient outcomes by providing advanced medical solutions for critical conditions related to cerebral blood flow.
Anulex Technologies
Series D in 2009
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).
iScience Interventional
Series F in 2009
iScience Interventional specializes in developing innovative medical technologies for ophthalmic interventions. They focus on creating advanced microcatheters and imaging systems, enabling eye specialists to precisely administer therapies to specific locations within the eye. Additionally, they offer medical devices for canaloplasty procedures.
Primaeva Medical
Series C in 2009
Primaeva Medical is a privately held company focused on developing innovative devices for dermatologists, plastic surgeons, and other cosmetic/aesthetic physicians. The company specializes in creating tools designed to reverse the signs of aging, with a particular emphasis on skin tightening and rejuvenation. In 2009, Primaeva Medical introduced a groundbreaking fractional radiofrequency system aimed at providing predictable treatments for aging skin.
Respicardia
Series B in 2008
Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.
Transoma Medical
Series D in 2008
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.
Spineology
Series B in 2008
Spineology Inc. is a medical device company specializing in anatomy-conserving technology solutions for spine surgery. Founded in 1996 and headquartered in Saint Paul, Minnesota, the company offers a range of products designed to enhance surgical efficiency and improve patient outcomes. Its product lineup includes pedicular fixation systems like Threshold and Fortress, interbody fusion solutions such as Duo and Rampart, and biologics like the Prime liquid tissue matrix and Armor amniotic wound covering. Additionally, Spineology provides a variety of surgical instruments, including the Capture facet fixation system, VIA spinous process fixation system, and Medius midline retractor system, among others. The company focuses on using minimally invasive techniques to reduce post-operative pain and facilitate quicker recovery for patients suffering from spinal-related issues.
NovaSys
Venture Round in 2008
NovaSys Health is a prominent provider of managed healthcare services, operating one of the largest health plans in Arkansas. With approximately 11,000 contracted providers in the region and over 4,300 in Arkansas, the company emphasizes strong relationships with healthcare providers. It offers a range of health plans and related services, including customized solutions, provider relations, and eligibility and billing administration, catering to a diverse network of hospitals, physicians, and ancillary providers.
NOVASYS MEDICAL
Series D in 2008
$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.
CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in the research and development of innovative therapies and treatment solutions for cerebral ischemia. The company focuses on creating devices that control blood flow to the brain, specifically through its neuroflo and flocontrol products. These devices are designed to divert blood flow in patients, thereby helping to reduce the risk of strokes and heart attacks, particularly in individuals experiencing vasospasm and heart blockage. CoAxia aims to improve patient outcomes by providing advanced medical solutions for critical conditions related to cerebral blood flow.
Atritech is a private medical technology company based in Minneapolis, Minnesota, founded in 2000. The company specializes in developing minimally invasive technologies aimed at preventing strokes related to atrial fibrillation. Their flagship product, the WATCHMAN Left Atrial Appendage Closure Technology, is designed to offer a permanent alternative to long-term anticoagulation therapy for patients with non-valvular atrial fibrillation who are at risk of stroke. The device works by closing off the left atrial appendage, preventing harmful blood clots from entering the bloodstream and causing strokes or other complications. The WATCHMAN Device has been CE Marked and is available in many markets outside the United States, while it is currently under investigation in the U.S.
Pegasus Biologics
Series C in 2007
Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.
Transoma Medical
Series C in 2007
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.
Respicardia
Series A in 2006
Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.
CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in the research and development of innovative therapies and treatment solutions for cerebral ischemia. The company focuses on creating devices that control blood flow to the brain, specifically through its neuroflo and flocontrol products. These devices are designed to divert blood flow in patients, thereby helping to reduce the risk of strokes and heart attacks, particularly in individuals experiencing vasospasm and heart blockage. CoAxia aims to improve patient outcomes by providing advanced medical solutions for critical conditions related to cerebral blood flow.
Anulex Technologies
Series C in 2006
Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).
Uptake Medical
Series A in 2006
Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.
Atritech is a private medical technology company based in Minneapolis, Minnesota, founded in 2000. The company specializes in developing minimally invasive technologies aimed at preventing strokes related to atrial fibrillation. Their flagship product, the WATCHMAN Left Atrial Appendage Closure Technology, is designed to offer a permanent alternative to long-term anticoagulation therapy for patients with non-valvular atrial fibrillation who are at risk of stroke. The device works by closing off the left atrial appendage, preventing harmful blood clots from entering the bloodstream and causing strokes or other complications. The WATCHMAN Device has been CE Marked and is available in many markets outside the United States, while it is currently under investigation in the U.S.
Transoma Medical
Series B in 2005
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.
Myocor is a medical company based in Minnesota, founded in 1996, that specializes in developing and distributing therapeutic products aimed at treating mitral regurgitation and heart failure. The company focuses on creating medical devices that alter the physiology of heart failure, ultimately enhancing clinical outcomes for patients with late-stage heart conditions. One of its notable innovations is the Coapsys device, which utilizes pads and a tensioned string to reshape an enlarged heart and improve the functionality of a leaky mitral valve. By providing these advanced technologies, Myocor seeks to improve cardiac function and offer effective solutions for individuals suffering from heart-related ailments.
Transneuronix
Series B in 2004
Transneuronix, Inc. is a privately held medical device company focused on the treatment of obesity by stimulation of the stomach with an implantable pacemaker-like device.
Disc Dynamics
Series E in 2004
Disc Dynamics is a healthcare company. They design and develop medical products. The Company offers surgical alternatives for the treatment of lower back problems and disc diseases. It offers DASCOR Disc arthroplasty system, a catheter-based minimally invasive nucleus replacement technology for the treatment of degenerated lumbar discs. Disc Dynamics was founded by Jeffrey Felt in 2000 and is headquartered in Eden Prairie, Minnesota.
NOVASYS MEDICAL
Series C in 2004
$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.
Alliance Medical Corporation
Series E in 2002
Alliance Medical is a reprocessor of medical devices. The company was founded by Rick Ferreira and is based in Phoenix, Arizona.
Celleration
Series B in 2002
Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.
NOVASYS MEDICAL
Series B in 2001
$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.
Ican
Venture Round in 2000
Ican Inc., is a provider of Internet-based information and tools for health professionals.
Ican
Venture Round in 2000
Ican provides Internet-based information and tools for health professionals.
Agiliti is a provider of healthcare technology management services, focusing on delivering essential IT infrastructure and applications tailored to the needs of the healthcare industry. The company offers a range of services, including clinical engineering, equipment rental, imaging services, and onsite management. By ensuring 24/7 server uptime and end-to-end accountability for IT systems, Agiliti enables healthcare organizations to effectively manage their technology needs. This allows clients to concentrate on their core operations while benefiting from flexible solutions designed to support their growth and enhance service delivery in the healthcare sector.